(Q38401300)

English

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

scientific article published on 28 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer (English)

1 reference

Europe PubMed Central

2 September 2017

12

object named as

Toshihiko Doi

1 reference

Europe PubMed Central

2 September 2017

23

object named as

Atsushi Ohtsu

1 reference

Europe PubMed Central

2 September 2017

author name string

Kohei Shitara

1

1 reference

Europe PubMed Central

2 September 2017

Kei Muro

2

1 reference

Europe PubMed Central

2 September 2017

Yasuhiro Shimada

3

1 reference

Europe PubMed Central

2 September 2017

Shuichi Hironaka

4

1 reference

Europe PubMed Central

2 September 2017

Naotoshi Sugimoto

5

1 reference

Europe PubMed Central

2 September 2017

Yoshito Komatsu

6

1 reference

Europe PubMed Central

2 September 2017

Tomohiro Nishina

7

1 reference

Europe PubMed Central

2 September 2017

Kensei Yamaguchi

8

1 reference

Europe PubMed Central

2 September 2017

Yoshihiko Segawa

9

1 reference

Europe PubMed Central

2 September 2017

Yasushi Omuro

10

1 reference

Europe PubMed Central

2 September 2017

Takao Tamura

11

1 reference

Europe PubMed Central

2 September 2017

Seigo Yukisawa

13

1 reference

Europe PubMed Central

2 September 2017

Hirofumi Yasui

14

1 reference

Europe PubMed Central

2 September 2017

Fumio Nagashima

15

1 reference

Europe PubMed Central

2 September 2017

Masahiro Gotoh

16

1 reference

Europe PubMed Central

2 September 2017

Taito Esaki

17

1 reference

Europe PubMed Central

2 September 2017

Michael Emig

18

1 reference

Europe PubMed Central

2 September 2017

Kumari Chandrawansa

19

1 reference

Europe PubMed Central

2 September 2017

Astra M Liepa

20

1 reference

Europe PubMed Central

2 September 2017

Hansjochen Wilke

21

1 reference

Europe PubMed Central

2 September 2017

Yukako Ichimiya

22

1 reference

Europe PubMed Central

2 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

28 October 2015

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

19

1 reference

Europe PubMed Central

2 September 2017

3

1 reference

Europe PubMed Central

2 September 2017

927-938

1 reference

Europe PubMed Central

2 September 2017

https://scigraph.springernature.com/pub.10.1007/s10120-015-0559-z

0 references

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Disparities in gastric cancer chemotherapy between the East and West

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Geographic differences in approach to advanced gastric cancer: Is there a standard approach?

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0559-Z

21 January 2018

A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26510663

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26510663

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26510663

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10120-015-0559-Z

1 reference

Europe PubMed Central

2 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38401300&oldid=2163917973"